Farmeconomia. Health economics and therapeutic pathways
Not a member yet
496 research outputs found
Sort by
Sicilia
Get PDFIn Sicily region 39,6% of women (aged 25-64) are screened regularly, meaning every 3 years.
Considering regional tariffs and vaccine acquisition cost, the vaccination of 12-year-old girls with a 90% coverage could prevent 169 cases of cervicocarcinoma and 68 related deaths and thus results to be cost-effective (15.534 €/QALY). When the vaccination programme is extended to 16-year-old girls a further 181 cancer cases and 75 deaths could be prevented, with a very similar cost-effectiveness ratio. In Sicily region, the net cost for woman vaccinated is 171 € for the single cohort and 176 € for the multiple cohort
Basilicata
Get PDFIn Basilicata region 57,5% of women (aged 25-64) are screened regularly, meaning every 3 years. Considering regional tariffs and vaccine acquisition cost, the vaccination of 12-year-old girls with a 90% coverage could prevent 14 cases of cervicocarcinoma and 6 related deaths and thus results to be cost-effective (20.169 €/QALY). When the vaccination programme is extended to 16-year-old girls a further 15 cancer cases and 6 deaths could be prevented, with a very similar cost-effectiveness ratio. In Basilicata region, the net cost for woman vaccinated is 185 € for the single cohort and 189 € for the multiple cohort
Calabria
Get PDFIn Calabria region 36,1% of women (aged 25-64) are screened regularly, meaning every 3 years. Considering regional tariffs and vaccine acquisition cost, the vaccination of 12-year-old girls with a 90% coverage could prevent 66 cases of cervicocarcinoma and 27 related deaths and thus results to be cost-effective (14.934 €/QALY). When the vaccination programme is extended to 16-year-old girls a further 72 cancer cases and 29 deaths could be prevented, with a very similar cost-effectiveness ratio. In Calabria region, the net cost for woman vaccinated is 175 € for the single cohort and 179 € for the multiple cohort
Emilia Romagna
Get PDFIn Emilia Romagna region 77,6% of women (aged 25-64) are screened regularly, meaning every 3 years. Considering regional tariffs and vaccine acquisition cost, the vaccination of 12-year-old girls with a 90% coverage could prevent 51 cases of cervicocarcinoma and 22 related deaths and thus results to be cost-effective (29.903€/QALY). When the vaccination programme is extended to 16-year-old girls a further 47 cancer cases and 20 deaths could be prevented, with a very similar cost-effectiveness ratio. In Emilia Romagna region, the net cost for woman vaccinated is 177€ for the single cohort and 180€ for the multiple cohort
Valle d’Aosta
Get PDFIn Aosta Valley region 77,9% of women (aged 25-64) are screened regularly, meaning every 3 years.
Considering regional tariffs and vaccine acquisition cost, the vaccination of 12-year-old girls with a 90% coverage could prevent 2 cases of cervicocarcinoma and 1 related death and thus results to be cost-effective (33.211 €/QALY). When the vaccination programme is extended to 16-year-old girls a further 1 cancer case could be prevented, with a very similar cost-effectiveness ratio. In Aosta Valley region, the net cost for woman vaccinated is 209 € for the single cohort and 211 € for the multiple cohort
The discovery of “sale amarissimo antifebbrile” (“bitter febrifugal saline”) by Bartolommeo Rigatelli, i.e. the origins of pharmacoeconomics
No full textWhen considering the history of salycilates, it has to be underlined that a number of Italian scientists made significant contributions on such a topic. Among these, two pharmacists, Bartolommeo Rigatelli in Verona and Francesco Fontana in Lazise, carried out the first extraction of the active component of willow bark in 1824. Rigatelli named the drug “sale amarissimo antifebbrile” (“bitter febrifugal saline”). In his report some references of pharmacoeconomics are sketched out, thus indicating the attention that the Austrian government on the North Italian districts gave to the management policy. In fact, Rigatelli carried out an economic account of the use of salicin extracts as an antipyretic agent instead of the chincona bark which had been imported from South America at that time and was very expensive. This historical report gives rise to outline a brief history of pharmacoeconomics
Budget impact of vildagliptin
No full textIntroduction: to evaluate the impact on the Italian National Health Service (NHS) budget of the recent introduction of the DPP-4 inhibitor vildagliptin in combination treatment for NIDDM patients. Methods: NIDDM patients eligible to vildagliptin treatment were identified and quantified based on approved indications and prevalence data review; adequate alternative strategies were identified; direct medical costs associated with competing strategies were calculated according to national practice and prices (drug acquisition, therapeutic monitoring, cost for managing severe adverse events – severe hypoglycemia events, fractures, new heart failure cases) and the NHS budgetary impact was estimated according to market penetration assumptions (base-case: 5% and 10% for the first and second year, respectively). Results: patients estimated eligible for vildagliptin in Italy are about 237,500: pts inadequately controlled with metformin monotherapy (166,500), pts inadequately controlled with sulfonylurea monotherapy and intolerant/contraindicated to metformin (70,200), and those inadequately controlled with thiazolidinedione monotherapy (800). Costing and comparing of the vildagliptin-based and competing strategies revealed differences in both directions, depending on patient subgroup. Assuming uniform penetration among identified patient subgroups, vildagliptin introduction is expected to raise NHS costs by 2,750,000 Euro in the first and by 5,500,000 Euro in the second year, respectively representing 1,6% and 3,2% of the estimated total management cost of this patient population. Conclusions: the introduction of vildagliptin in the treatment of Italian NIDDM patients offers a new therapeutic option for three inadequately controlled NIDDM subpopulations; the financial impact on Italian NHS expenditures depends on patient selection and can be expected not to exceed 2-3% of the currently dedicated budget in the first two years
Evaluation of health resources expenditure in two groups of psychotic patients treated with olanzapine and typical neuroleptics in a Italian Mental Health Department in Calabria Region
No full textNumerous Italian and international trials have studied the global costs of treatment with olanzapine and typical neuroleptics. Our analysis confirms those results. In our study, treatment with olanzapine, as compared to typical neuroleptics, was associated with a greater reduction in emergency interventions (hospitalisations), with an increased use of rehabilitation services and with a small increase in the number of working days. The differences between the two groups for this variable were not great, while the differences in the assessment scores appeared important and statistically significant. The results of present study are relative to the practice of one Italian Mental Health Department and, for this reason, cannot be generalized. Anyway, they are another indication of increased efficiency of atypicals treatment over older neuroleptics in schizophrenia
